News Briefing channel feed

Iso­Plex­is bags $25M to stoke T cell ther­a­py buzz; Col­lab­o­ra­tion be­tween X4 and LLS; New CMO at Pre­ci­sion Bio­sciences

7 years ago

Take­da fore­casts $1.7B loss af­ter Shire in­te­gra­tion; Flag­ship's pre­clin­i­cal biotech Ax­cel­la clos­es IPO with $71M+ haul

7 years ago

Bi­cy­cle sets terms for $65M IPO; Lil­ly's Cyra­mza wins fifth can­cer ap­proval

7 years ago

Lam­bast­ed by AIDS ac­tivists about Tru­va­da pric­ing, Gilead of­fers CDC drug sup­ply deal; Fi­bro­Gen MACE mis­com­mu­ni­ca­tion leaves in­vestors dis­ori­ent­ed

7 years ago

Gilead says on­ly Te­va can mar­ket Tru­va­da gener­ic; Den­ver nar­row­ly votes to de­crim­i­nal­ize "mag­ic mush­rooms"

7 years ago

BioN­Tech nabs PhI an­ti­body and a new US base out of bank­rupt­cy; Pfiz­er wins con­di­tion­al drug OK

7 years ago

Con­fo Ther­a­peu­tics rais­es €30 mil­lion; Waylivra re­ceives ap­proval from EU; end­point met for Mer­ck­'s Bel­som­ra in PhI­II tri­al

7 years ago

Es­pe­ri­on shares surge as FDA waves off pan­el re­view; Adap­ti­m­mune buoyed by a pos­i­tive da­ta snap­shot

7 years ago

FDA ex­pands ap­proval of Agios' Tib­so­vo; As­traZeneca's long-act­ing di­a­betes drug se­cures US nod

7 years ago

Cel­gene part­ners on Phase 0 can­cer drug stud­ies; FDA lifts clin­i­cal hold on Xen­cor's bis­pe­cif­ic

7 years ago

Ab­b­Vie nabs pe­di­atric OK for hep C drug Mavyret; Glen­mark launch­es cheap­er SGLT2 in­hibitor in In­dia

7 years ago

As­traZeneca teams with Benev­o­len­tAI on dis­cov­ery, re­search; Cam­bridge spin­out rais­es seed cash for pro­tein degra­da­tion work

7 years ago

Por­to­la gets EU clear­ance to mar­ket An­dexxa un­der new name; Four biotechs set terms for Nas­daq de­but

7 years ago

Cel­gene sub­mits EU mar­ket­ing pitch for lus­pa­ter­cept; Bausch Health wins FDA ap­proval for top­i­cal pso­ri­a­sis treat­ment

7 years ago

Af­ter Bio­gen ex­it, Mit­subishi Tan­abe Phar­ma links up with Sal­ix to de­vel­op amise­limod; Two drug de­vel­op­ers set up an­tibi­ot­ic col­lab­o­ra­tion

7 years ago

GSK plans $100M makeover of US man­u­fac­tur­ing site; La Jol­la Phar­ma gets a 'break­through' with late-stage drug

7 years ago

Re­gen­eron's Schleifer: Amer­i­can pub­lic com­pa­nies should fund 'in­fra­struc­ture bank'; Sher­lock clos­es $49M round for CRISPR di­ag­nos­tic work

7 years ago

Pfiz­er on­col­o­gy R&D ex­ec heads to Aduro as new CMO; Army dumps Tonix re­search con­tract

7 years ago

Gen­fit wins BTD sta­tus at FDA for its lead drug for liv­er dis­ease; Idor­sia out­lines $530M '19 spend­ing plans on late-stage R&D

7 years ago

Turn­ing Point un­veils $166M IPO; Aque­s­tive's rilu­zole film prod­uct is ac­cept­ed for FDA re­view

7 years ago

NICE backs Akcea's Tegse­di; EMA re­stricts Lem­tra­da use while it probes safe­ty con­cerns

7 years ago

In­sys pro­motes CFO to the helm as Saeed Mo­ta­hari hits the ex­it; Gele­sis gets OK to mar­ket weight loss treat­ment

7 years ago

Mer­ck­'s Keytru­da wins US ap­proval for wider lung can­cer pop­u­la­tion; CymaBay breaks out pos­i­tive da­ta from on­go­ing PBC study

7 years ago

Cam­brex com­pletes $24M API man­u­fac­tur­ing fa­cil­i­ty; Twist and LakePhar­ma part­ner on an­ti­body con­tract work

7 years ago
First page Previous page 50515253545556 Next page Last page
A service from the Financial Times